Spiro Rombotis Cyclacel's guest appearances

Spiro Rombotis Cyclacel

Empowered Patient Podcast

OwlTail

Spiro Rombotis

Spiro Rombotis is the CEO of Cyclacel, which is identifying biomarkers relevant to their drug fadraciclib's mechanism to increase the chance for success in trials for a wide range of cancers. Cyclacel has seen activity of fadra as a single agent in phase one patients with women's cancers like endometrial, ovarian, and breast cancers, and lymphomas, liver cancer, and colorectal cancer. Spiro explains, "Before the pandemic, we had an intravenous version of fadra administered to patients in a single center study at Dana-Farber Cancer Institute in Boston. And although the drug was active in these patients, it is clear during the pandemic and now, at hopefully the tail end of the pandemic, that oral therapies have dramatic advantages. Not only because patients don't have to be exposed to the virus, which is not a very good idea for a cancer patient who is more vulnerable than the general population, but also because of the ability and convenience of receiving a drug orally and staying at home." "We take patients regardless of tumor type, the anatomy, or where the tumor started but based on biomarkers. Biomarkers are biological parameters that we test with patients' blood or tissue before they go on the study based on the drug’s mechanism. If they have a high level of these markers, they can enroll in the basket cohort, which allows us to have a shot at the goal by identifying patients who might have a higher chance of response than the population at large." @CyclacelPharma #Cyclacel $CYCC #Onco #Oncology #Cancer #CancerResistance #CancerDrug #SolidTumor #Tumor #Fadraciclib #Fadra #CYC140 #CellCycle #Mitosis #Apoptosis cyclacel.com Download the transcript here

Spiro Rombotis is the CEO of Cyclacel, which is identifying biomarkers relevant to their drug fadraciclib's mechanism to increase the chance for success in trials for a wide range of cancers. Cyclacel has seen activity of fadra as a single agent in phase one patients with women's cancers like endometrial, ovarian, and breast cancers, and lymphomas, liver cancer, and colorectal cancer. Spiro explains, "Before the pandemic, we had an intravenous version of fadra administered to patients in a single center study at Dana-Farber Cancer Institute in Boston. And although the drug was active in these patients, it is clear during the pandemic and now, at hopefully the tail end of the pandemic, that oral therapies have dramatic advantages. Not only because patients don't have to be exposed to the virus, which is not a very good idea for a cancer patient who is more vulnerable than the general population, but also because of the ability and convenience of receiving a drug orally and staying at home." "We take patients regardless of tumor type, the anatomy, or where the tumor started but based on biomarkers. Biomarkers are biological parameters that we test with patients' blood or tissue before they go on the study based on the drug’s mechanism. If they have a high level of these markers, they can enroll in the basket cohort, which allows us to have a shot at the goal by identifying patients who might have a higher chance of response than the population at large." @CyclacelPharma #Cyclacel $CYCC #Onco #Oncology #Cancer #CancerResistance #CancerDrug #SolidTumor #Tumor #Fadraciclib #Fadra #CYC140 #CellCycle #Mitosis #Apoptosis <a href="http://cyclacel.com" rel="noopener nofollow" target="_blank">cyclacel.com</a> <a href="http://empoweredpatientradio.com/streamlining-clinical-trials-for-fadra-in-solid-tumors-and-blood-cancers-with-spiro-rombotis-cyclacel-transcript" rel="noopener nofollow" target="_blank">Download the transcript here</a>